Daily Management Review

ADHD Can Be Treated With ‘Cotempla XR-ODT’ Shows Neos Therapeutics’ Studies


10/31/2015


Neos Therapeutics comes up with the Cotempla XR-ODT for the treatment of ADHD



The Neos Therapeutics, Inc. has “extended” the release of the “product candidates” who were involved in the “development for the treatment of attention deficit hyperactivity disorder” in short ADHD. The announcement presented “new data” during the 62nd annual gathering of the American Academy of Child and Adolescent Psychiatry that took place in Texas.
 
Two results were brought forward wherein “clinical trials” of “Company's methylphenidate (MPH) XR” in the form “orally disintegrating tablet” were “presented”. Moreover, the third phase of the study incorporates “treatment with Cotempla XR-ODT”, whereby the results demonstrated “a statistically significant improvement in ADHD symptom control” in comparison to the “placebo across the classroom day” among the children suffering from ADHD.
 
The Ann Childress from the “University of Nevada School of Medicine” who is also the president of the “Center for Psychiatry and Behavioral Medicine” situated at Nevada, Las Vegas, said:
"ADHD is a condition that causes significant distress for patients and caregivers. Although there are a number of effective extended-release medications currently on the market, most formulations consist of tablets or capsules that must be swallowed whole. Some capsules can be opened and sprinkled on certain foods, but must be ingested immediately without chewing. Cotempla XR-ODT disintegrates in the mouth without water and the PK and efficacy studies demonstrate a profile that is consistent with once-daily dosing."
 
While, the C.E.O and the President of Neos Therapeutics, Vipin K. Garg, Ph.D. remarked:
"An extended release orally disintegrating tablet therapy, if approved, could provide patients the combination of two key drug delivery attributes - an extended-release profile which would allow for once-daily dosing and an ODT dosage designed to disintegrate in the mouth without water - in one formulation”.
 
However the StreetInsider informs that:
“In a randomized, multicenter, double-blind, placebo-controlled, parallel group study of 87 children with ADHD, treatment with Cotempla XR-ODT provided greater ADHD symptom control compared to placebo on the Swanson, Kotkin, Agler, M-Flynn and Pelham (SKAMP)-Combined score averaged across the classroom day. The SKAMP-Combined scores (least square [LS] mean [confidence interval (95% CI)]) averaged over the classroom testing day were 14.3 (12.2, 16.4) for the Cotempla XR-ODT group and 25.3 (23.0, 27.6) for the placebo group. The LS mean difference (95% CI) between the treatment groups was −11.04 [(−13.9, −8.20); P<0.0001]”.



References:
www.streetinsider.com
 







Science & Technology

Top ten hi-tech events of the year

Tesla Considering Designing And Developing AI Chips On Its Own To Support Its Auto-Pilot Project

Verizon to introduce 5G in five American cities in 2018

Airbus, Rolls-Royce, Siemens to create an electric aircraft

Study Finds Treatment Efficacy Could Be Sacrificed For Reduced Side Effects In Cancer Therapies By Patients

Some Information About Their Self-Driving Car Research Has Been Disclosed By Apple Scientists For The First Time

A Massive Data Breach Was Covered Up By Uber By Paying Up Hackers

A City Is Can Be Converted To A Living Organism, Showcases China’s Huawei

Workers Would Be Helped To Lift More By These Robotic Vests

British Parliament to assess impact of e-cigarettes

World Politics

World & Politics

15 countries with the highest level of organized crime

Athens agreed with international lenders

EU Pressure Reportedly Forces UK To Bow Down, Could Agree To Pay £50bn For Brexit Divorce

$1 Billion Is The Price For Freedom For Arrested Saudi Prince In Corruption Crackdown: Reports

U.S. Capital Washington Appears To Be In Range Of The Latest Missile Launched By North Korea

Ten biggest fears of millennials

Ireland Cancels The Need Of A Veto For Brexit Summit With Its Solidarity

Separatists of Catalonia are divided over the political course